Sinclair announced his resignation as president of the Academy for Health and Lifespan Research after receiving criticism from other longevity researchers for making claims about age-reversal potential of supplements and techniques that he co-created.
Sinclair has advocated for partial cellular reprogramming using chemicals to reset epigenetic patterns of cells. Recently he gave an interview about this work to American engineer and entrepreneur Peter Diamandis.
Information Theory of Aging
The Information Theory of Aging (ITOA) suggests that aging occurs as the result of gradual degradation in differentiated cells’ epigenomic information over time. A cell is capable of self-repair, yet repeated cycles of repairs can create errors in its genome that negatively impact how cells operate – this eventually causes cells to stop performing their original functions altogether – similar to how computers require rebooting to properly function again.
Scientists employ various approaches for reprogramming cells, including cell transplantation and gene therapy, but these techniques are expensive, time consuming, and have side effects such as tumor formation or organ rejection that don’t address age-related disease causes.
Partial cellular reprogramming is a more innovative technique. This technique employs Yamanaka factor genes to activate natural repair mechanisms within cells, yet activates them for shorter periods than full cellular reprogramming – this allows cells to partially reverse their aging changes without going back into stem cell mode. This approach has shown promising results in both preventing and reversing glaucoma-related blindness in mice and monkeys as well as restoring vision for aged monkeys.
Dr. Sinclair holds that reversing aging may soon be within our grasp, and predicts that within 10 years pills will be available that can reverse or at least slow it, and in some cases even double human lifespan. Unfortunately, his predictions remain highly speculative and some have accused him of overhyping his research or pushing unproven products from companies with which he has financial interests.
Sinclair differs from most scientists in his belief that to increase longevity effectively we should not pursue disease specific therapies; rather, reversing biological processes responsible for aging should be our goal.
Sinclair is an influential researcher in regenerative medicine, co-founding several companies that develop supplements and techniques designed to slow or even reverse aging, published a book about it, as well as contributing numerous scientific articles on it. Although his claims on social media and interviews may have caused some controversy, Sinclair still believes researchers will create an anti-aging pill soon enough.
Partial Cellular Reprogramming
Researchers are discovering ways to reverse cell aging by partially resetting epigenetic alterations, known as partial cell reprogramming. To be effective, exposure of cells to specific tissues for brief periods and with specific factors must minimize cancer risk without disrupting cell differentiation; such challenges make partial cell reprogramming an attractive choice among scientists.
Harvard Medical School researchers led by a team of researchers demonstrated in 2020 that partial reprogramming could reverse the effects of aging in mice through partial expression of Oct4, Sox2, and Klf4 (OSK) reprogramming factors. Their expression improved visual function among progeric mice while simultaneously decreasing amyloid-beta plaques and other signs of brain senescence markers; finally they noted how OSK stimulation stimulated regeneration of pancreatic beta cells and satellite cells within skeletal muscle.
Nelly Olova of the University of California at Berkeley conducted another study which confirmed cyclic partial reprogramming can reduce epigenetic cell ageing and enhance tissue regeneration. Her research demonstrated how OSK-mediated partial reprogramming could increase stem cell proliferation across multiple tissues including skin tissue where it enhanced wound healing while decreasing fibrotic disease incidence, which accounts for 45% of disease deaths worldwide.
Researchers caution that further studies must be conducted to ascertain the safety and efficacy of partial reprogramming, in particular by testing it at organ level rather than individual cells. They must also explore differences between cyclic and continuous partial reprogramming which will prove crucial when translating this research to clinical practice.
Dr. Sinclair and other longevity researchers are exploring partial reprogramming as an approach to treating specific diseases. This type of research is more practical than trying to reverse aging entirely in whole organisms; yet still yielding breakthroughs in the field. Furthermore, successes achieved within individual organs could provide data necessary for the development of targeted medicines for specific ailments.
Artificial Intelligence-Generated Molecules
Recent years have witnessed artificial intelligence become an integral component of pharmaceutical industry efforts to develop anti-ageing medications. Combining generative molecular design with structural analysis, protein-protein docking and other tools that predict how molecules will perform under biological tests has become one effective approach to AI use in drug discovery efforts.
But an AI algorithm still faces one major hurdle: verifying whether its produced molecules are useful in practice. To do this, generative AI models must be tested against real-world chemistry and medicinal chemistry criteria; one key metric being whether generated molecules can actually be made in a lab; if an in silico molecule looks promising but becomes impossible or costly to synthesize; so increasing numbers of teams are turning to generative AI to develop compounds which can be synthesized and tested in the lab.
Healthspan XPRIZE offers one such incentive. The prize seeks to find combinations of drugs which address all four hallmarks of aging and can extend human health by at least 10 years; the first team to do so will win it all.
Scientists may still be learning how to effectively apply generative AI, but they’ve made considerable strides already. One such platform is AgeXtend: an explainable AI platform designed to find new geroprotectors – compounds which protect against the signs of ageing – using a modular approach which evaluates each molecule’s geroprotective potential, toxicity risks, protein targets and likely protein targets before comparing those results against an extensive library of over one billion chemicals such as small molecules, phytochemicals cellular and microbial metabolites so as to find those with anti-ageing properties.
However, it must be remembered that AI systems do not seek to replace human expertise in early-stage drug discovery. For best results, AI output should be treated as high-quality starting points for expert refinement and experimental validation, rather than completed designs that can be approved solely on model metrics alone. It is thus imperative that people remain part of this process.
Age-Reversing Pills
Harvard geneticist David Sinclair, cofounder of Life Biosciences and known for making grandiose claims about anti-aging treatments that have fallen short, recently gave an interview to Peter Diamandis for his new book Chasing Immortality. During their conversation, they discussed recent advancements in longevity research while making an astonishing prediction: within 10 years scientists will be able to create pills capable of targeting specific genes to reverse aging in tissues throughout the body.
Sinclair and his team’s research builds upon Shinya Yamanaka’s 2012 Nobel Prize-winning work that demonstrated how adult cells could turn back the clock by turning into stem cells. Sinclair and his team have created an easier method for doing this through partial rather than full cellular reprogramming; using Yamanaka factor genes only for shorter time periods and keeping cells from becoming pluripotent stem cells.
Sinclair and his team are using AI research to create molecules that mimic partial cell reprogramming in pill form, potentially increasing lifespan considerably when human trials commence.
